


Microtubule inhibitor 2

Cat. No.:	HY-145828
Molecular Formula:	C ₂₀ H ₂₃ NO ₇
Molecular Weight:	389.4
Target:	Ferroptosis; Microtubule/Tubulin
Pathway:	Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Microtubule inhibitor 2 is a potent and selective, orally active microtubule inhibitor. Microtubule inhibitor 2 triggers cell death through ferroptosis. Microtubule inhibitor 2 shows antitumor activity ^[1] .																
In Vitro	<p>Microtubule inhibitor 2 (compound 33) (48 h) shows antiproliferative activity with IC₅₀ values of 0.01, 0.02, 0.02, 0.04, 0.05 μM for A549, HeLa, A2780, HCT-8, MCF-7 cells, respectively^[1].</p> <p>Microtubule inhibitor 2 shows selective toward normal human cells and cancer cells (IC₅₀s of 0.01, 0.04, 1.45, 1.32, 0.54 μM for A549, quiescent HUVECs, LO2, HLF, MCF-10A cells, respectively)^[1].</p> <p>Microtubule inhibitor 2 (48 h) shows antiproliferative activity toward drug-resistant cancer cells (IC₅₀s of 0.02, 0.07, 0.04 for A549/ADM, HCT-8/VCR, A2780/TAX cells, respectively)^[1].</p> <p>Microtubule inhibitor 2 (5, 10, 20 nM; 24 h) dramatically disrupts the dynamic balance of the tubulin-microtubule system, induces the multipolarization of the mitotic spindle, and interfered with the mitosis of A549 cells^[1].</p> <p>Microtubule inhibitor 2 (5, 10, 20 nM, 24 h, 48 h) arrests cell cycle progression at the G₂/M phase in a dose and time-dependent manner^[1].</p> <p>Microtubule inhibitor 2 triggers cell death through ferroptosis rather than apoptosis^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549, HeLa, A2780, HCT-8, MCF-7 cells</td> </tr> <tr> <td>Concentration:</td> <td></td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Showed antiproliferative activities with IC₅₀ values of 0.01, 0.02, 0.02, 0.04, 0.05 μM for A549, HeLa, A2780, HCT-8, MCF-7 cells, respectively.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549 cells</td> </tr> <tr> <td>Concentration:</td> <td>5, 10, 20 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h, 48 h</td> </tr> <tr> <td>Result:</td> <td>Arrested cell cycle progression at the G₂/M phase in a dose and time-dependent manner.</td> </tr> </table>	Cell Line:	A549, HeLa, A2780, HCT-8, MCF-7 cells	Concentration:		Incubation Time:	48 h	Result:	Showed antiproliferative activities with IC ₅₀ values of 0.01, 0.02, 0.02, 0.04, 0.05 μM for A549, HeLa, A2780, HCT-8, MCF-7 cells, respectively.	Cell Line:	A549 cells	Concentration:	5, 10, 20 nM	Incubation Time:	24 h, 48 h	Result:	Arrested cell cycle progression at the G ₂ /M phase in a dose and time-dependent manner.
Cell Line:	A549, HeLa, A2780, HCT-8, MCF-7 cells																
Concentration:																	
Incubation Time:	48 h																
Result:	Showed antiproliferative activities with IC ₅₀ values of 0.01, 0.02, 0.02, 0.04, 0.05 μM for A549, HeLa, A2780, HCT-8, MCF-7 cells, respectively.																
Cell Line:	A549 cells																
Concentration:	5, 10, 20 nM																
Incubation Time:	24 h, 48 h																
Result:	Arrested cell cycle progression at the G ₂ /M phase in a dose and time-dependent manner.																

In Vivo

Microtubule inhibitor 2 (10 mg/kg; p.o.) displays excellent oral bioavailability ($F\% = 69.45$)^[1].

Microtubule inhibitor 2 (10 mg/kg; i.p.; every other day for 22 days) shows antitumor activity and the level of tumor growth inhibition was 78.63%^[1].

Pharmacokinetic Parameters of Microtubule inhibitor 2 in Male Institute of Cancer Research (ICR) mice (18–23 g)^[1].

	p.o.	i.v.
dose (mg/kg)	10	1
$T_{1/2}$ (h)	2.12	0.62
T_{max} (h)	0.25	0.08
T_{max} (ng/mL)	776.31	871.40
$AUC_{(0-t)}$ (h ng ⁻¹ mL)	2432.04	350.19
$AUC_{(0-\infty)}$ (h ng ⁻¹ mL)	2463.76	353.02
MRT (h)	2.57	0.68
CL (mL h ⁻¹ kg ⁻¹)	-	2855.67
F %	69.45	-

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Institute of Cancer Research (ICR) mice (18–23 g) ^[1]
Dosage:	10 mg/kg
Administration:	
Result:	Displayed excellent oral bioavailability ($F\% = 69.45$).
Animal Model:	Male BALB/c nude mice (5 weeks old, 18–20 g) (A549 xenograft models) ^[1]
Dosage:	10 mg/kg
Administration:	i.p.; every other day, 22 days
Result:	Showed antitumor activity and the level of tumor growth inhibition was 78.63%.

REFERENCES

[1]. Zhou J, et al. Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis. *J Med Chem.* 2022; 65(6):4687-4708.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA